Pharmacotherapeutic potential of Vitis vinifera(grape) in age-related neurological diseases / Potencial farmacoterapéutico de Vitis vinifera(uva) en enfermedades neurológicas asociadas a la edad

Age-related neurological disorders (ANDs), including neurodegenerative diseases, are complex illnesses with an increasing risk with advancing years. The central nervous system's neuropathological conditions, including oxidative stress, neuroinflammation, and protein misfolding, are what define ANDs. Due to the rise in age-dependent prevalence, efforts have been made to combat ANDs. Vitis viniferahas a long history of usageto treat a variety of illness symptoms. Because multiple ligand sites may be targeted, Vitis viniferacomponents can be employed to treat ANDs. This is demonstrated by the link between the structure and action of these compounds. This review demonstrates that Vitis viniferaand its constituents, including flavonoids, phenolic compounds, stilbenoidsandaromatic acids, are effective at reducing the neurological symptoms and pathological conditions of ANDs. This is done by acting as an antioxidant and anti-inflammatory. The active Vitis vinifera ingredients have therapeutic effects on ANDs, as this review explains.

Las enfermedades neurológicas asociadas a la edad (AND, por su sigla en inglés) incluyendo las enfermedades neurodegenerativas, son enfermedades complejas con un riesgo creciente con la edad. Las condiciones neuropatológicas del sistema nervioso central, que incluyen el estrés oxidativo, la neuro inflamación, y el plegado erróneo de proteínas, son lo que define las AND. Debido al aumento en la prevalencia dependiente de la edad, se han hecho esfuerzos para combatir las AND. Vitis vinifera tiene una larga historia de uso para el tratamiento de síntomas. Puesto que puede hacer objetivo a muchos sitios ligando, los componentes de Vitis viniferase pueden utilizar para tratar AND. Esto se demuestra por el vínculo entre la estructura y la acción de estos compuestos. Esta revisión demuestra que la Vitis viniferay sus constituyentes, incluídos los flavonoides, componentes fenólicos, estilbenoides, y ácidos aromáticos, son efectivos para reducir los síntomas neurológicos y las condiciones patológicas de AND. Esto se produce por su acción como antioxidante y antiinflamatorio. Los ingredientes activos de Vitis vinifera tienen efectos terapéuticos en AND, y esta revisión lo explica.

Hipoparatiroidismo y calcificaciones cerebrales: reporte de caso / Hypoparathyroidism and brain calcifications: a case report

Introducción. El hipoparatiroidismo es una enfermedad caracterizada por la ausencia o concentraciones inadecuadamente bajas de hormona paratiroidea (PTH), que conduce a hipocalcemia, hiperfosfatemia y excreción fraccional elevada de calcio en la orina. Las calcificaciones del sistema nervioso central son un hallazgo frecuente en estos pacientes. Caso clínico. Mujer de 56 años con antecedente de hipotiroidismo, que ingresó por un cuadro de 6 días de evolución caracterizado por astenia, parestesias periorales y movimientos anormales de manos y pies. Las pruebas de laboratorio demostraron hipocalcemia, hiperfosfatemia y niveles bajos de hormona paratiroidea. Se realizó una tomografía computarizada de cráneo que mostró áreas bilaterales y simétricas de calcificaciones en hemisferios cerebelosos, ganglios basales y corona radiata. No se evidenciaron trastornos en el metabolismo del cobre y hierro. Se estableció el diagnóstico del síndrome de Fahr secundario a hipoparatiroidismo y se inició tratamiento con suplementos de calcio y vitamina D con evolución satisfactoria. Discusión. El síndrome de Fahr es un trastorno neurológico caracterizado por el depósito anormal de calcio en áreas del cerebro que controlan la actividad motora. Se asocia a varias enfermedades, especialmente, hipoparatiroidismo. La suplementación con calcio y vitamina D con el objetivo de normalizar los niveles plasmáticos de estos cationes es el tratamiento convencional. (AU)

Introduction. Hypoparathyroidism is a disease characterized by absence or inappropriately low concentrations of circulating parathyroid hormone, leading to hypocalcaemia, hyperphosphataemia and elevated fractional excretion of calcium in the urine. Central nervous system calcifications are a common finding in these patients. Case report. 56-year-old woman with a history of hypothyroidism who was admitted for a 6-day course of illness characterized by asthenia, perioral paresthesias, and abnormal movements of the hands and feet. Laboratory tests showed hypocalcemia, hyperphosphatemia, and low parathyroid hormone levels. A cranial computed tomography was performed. It showed bilateral and symmetrical areas of calcifications in the cerebellar hemispheres, basal ganglia, and radiata crown. No disorders of copper or iron metabolism were evident. The diagnosis of Fahr syndrome secondary to hypoparathyroidism was established and treatment with calcium and vitamin D supplements was started with satisfactory evolution. Discussion. Fahr's syndrome is a neurological disorder associated with abnormal calcium deposition in areas of the brain that control motor activity. It is associated with various diseases, especially hypoparathyroidism. The conventional treatment is supplementation with calcium and vitamin D, with the aim of normalizing their plasma levels. (AU)

Influence of growth hormone replacement on neurological and psychomotor development. Case report / Influência da reposição do hormônio do crescimento no desenvolvimento neuropsicomotor. Relato de caso

ABSTRACT The height response to the use of growth hormone in short height cases has already been confirmed in the literature. The influence of the insulin-like growth factor 1 (GH-IGF1) axis components on development, function, regeneration, neuroprotection, cognition, and motor functions has been evaluated in experimental studies and in adults with central nervous system lesions. However, there is still little research on the clinical impact of hormone replacement on neurological and psychomotor development. This report presents the case of a patient with excellent weight-height recovery and, even more surprisingly, neurological and psychomotor development in response to use of growth hormone. The result strengthens the correlation between experimental and clinical findings related to cerebral plasticity response to growth hormone in children. A preterm male patient with multiple health problems during the neonatal and young infancy period, who for six years presented with a relevant deficit in growth, bone maturation, and neurological and psychomotor development. At six years of age, he had low stature (z-score −6.89), low growth rate, and low weight (z-score −7.91). He was incapable of sustaining his axial weight, had not developed fine motor skills or sphincter control, and presented with dysfunctional swallowing and language. Supplementary tests showed low IGF-11 levels, with no changes on the image of the hypothalamus-pituitary region, and bone age consistent with three-year-old children — for a chronological age of six years and one month. Growth hormone replacement therapy had a strong impact on the weight-height recovery as well as on the neurological and psychomotor development of this child.

RESUMO A resposta estatural ao uso de hormônio do crescimento na baixa estatura já está comprovada na literatura. A influência dos componentes do eixo fator de crescimento semelhante à insulina tipo 1 (GH-IGF1) sobre desenvolvimento, função, regeneração, neuroproteção, cognição e funções motoras tem sido avaliada em estudos experimentais e em adultos com lesão de sistema nervoso central. No entanto, ainda são poucas as pesquisas sobre o impacto clínico da reposição hormonal no desenvolvimento neuropsicomotor. Este relato apresenta o caso de um paciente com excelente recuperação pôndero-estatural e, de forma ainda mais surpreendente, de desenvolvimento neuropsicomotor, em resposta ao uso de hormônio do crescimento. O resultado observado fortalece a correlação entre achados experimentais e clínicos, no que diz respeito à resposta da plasticidade cerebral ao hormônio do crescimento em crianças. Paciente do sexo masculino nasceu pré-termo com múltiplos agravos no período neonatal e de lactente jovem, e que, por 6 anos, apresentou deficit relevante do crescimento, na maturação óssea e do desenvolvimento neuropsicomotor. Aos 6 anos de idade, apresentava baixa estatura (escore Z de −6,89), baixa velocidade de crescimento e baixo peso (escore Z de −7,91). Era incapaz de sustentar o peso axial, não tinha desenvolvido habilidade motora fina e nem controle esfincteriano, e apresentava também disfunção na deglutição e na linguagem. Exames complementares mostraram IGF1 baixo, sem alterações na imagem da região hipotálamo-hipofisária e idade óssea compatível com 3 anos — para a idade cronológica de 6 anos e 1 mês. A terapia de reposição com hormônio do crescimento promoveu forte impacto na recuperação pôndero-estatural e também do desenvolvimento neuropsicomotor desta criança.

Charcot, Mitchell and Lees: neurology free thinkers and their experiences of psychoactive drugs / Charcot, Mitchell e Lees: livres-pensadores da neurologia e suas experiências com drogas psico-ativas

ABSTRACT Three world-famous neurologists, Charcot and Mitchell, in the 19th century, and Lees, in this century, all of whom had great scientific curiosity, experimented with the psychoactive drugs hashish, mescal and yagé, respectively, in an attempt to increase their knowledge of neurological diseases and how the brain works.

RESUMO Três mundialmente famosos neurologistas, Charcot e Mitchell, no século XIX, e Lees neste século, tiveram eles mesmos, experiências com drogas psico-ativas, com haxixe, mescalina e yagé, respectivamente, demonstrando a sua intensa curiosidade científica, na tentativa de aprimorar o seu conhecimento da função cerebral e das doenças neurológicas.

Cannabinoids in neurology – Brazilian Academy of Neurology / Canabinoides e seu uso em neurologia – Academia Brasileira de Neurologia

O uso do canabidiol em algumas condições neurológicas foi liberado pelo Conselho Regional de Medicina de São Paulo e pela Agência Nacional de Vigilância Sanitária (ANVISA). Especialistas em nome da Academia Brasileira de Neurologia prepararam uma posição crítica sobre o uso do canabidiol e outros derivados da cannabis em doenças neurológicas.

The use of cannabidiol in some neurological conditions was allowed by Conselho Regional de Medicina de São Paulo and by Agência Nacional de Vigilância Sanitária (ANVISA). Specialists on behalf of Academia Brasileira de Neurologia prepared a critical statement about use of cannabidiol and other cannabis derivatives in neurological diseases.

Hombre joven con déficit motor y lesiones inflamatorias intracerebrales: reporte de un caso clínico de Neuro-Behcet / Young man with motor deficit and intracerebral inflammatory lesions: a Neuro-Behcet case report

La enfermedad de Behçet (EB) es una patología inflamatoria vascular, multisistémica y recurrente. El fenómeno subyacente es una perivasculitis que afecta el territorio arterial y venoso. La mayor prevalencia de la enfermedad se encuentra en el Oriente y cuenca del Mediterráneo, en la llamada “Ruta de la Seda”. La prevalencia en Chile es desconocida. Las manifestaciones clínicas más frecuentes son úlceras orales y genitales recurrentes, uveítis, artritis, compromiso de sistema nervioso y vascular. El compromiso de SNC (Neuro-Behçet) varía entre 5 por ciento y 13 por ciento, y se divide en dos tipos: Intra-axial o parenquimatoso, más frecuente, más grave, con lesiones inflamatorias en tronco del encéfalo, en unión meso-diencefálica y región pontobulbar. Puede extenderse hacia diencéfalo, bulbo y médula espinal. El compromiso hemisférico es menos frecuente. Extra-axial, que se presenta como trombosis de senos venosos, y aneurismas, estenosis y disección arterial. El tratamiento del Neuro-Behçet intra-axial se basa en esteroides en dosis altas asociados a inmunosupresores, entre ellos, y dependiendo de la severidad, Metotrexato, Azatioprina, Ciclofosfamida, Micofenolato, y Anti-TNFα en casos refractarios o severos.

The highest prevalence of the disease is found in the East and the Mediterranean basin, in the so called “Silk Road”. The prevalence in Chile is unknown. The most frequent clinical manifestations are recurrent oral and genital ulcers, uveitis, arthritis, and CNS involvement (Neuro-Behçet). Neurological disease varies between 5 percent and 13 percent, and it can be divided into two types: Intra-axial or parenchymatous: more frequent, more severe, with inflammatory lesions involving the brainstem, midbrain, diencephalon and pontobulbar regions. It may extend into the spinal cord. Involvement of the brain hemispheres is less common. Extra-axial: also called “Neurovasculo Behçet”, less common and with better prognosis. It can manifests as venous sinus thrombosis, and aneurysm, stenosis, or arterial dissection of intracerebral or extracranial arteries. Treatment of Intra-axial Neuro-Behçet is based on high-dose steroids associated with immunosuppressive agents like: Methotrexate, Azathioprine, Cyclophosphamide, Mycophenolate, and anti α-TNF in refractory or severe disease.

Acidos grasos omega-3, enfermedades psiquiátricas y neurodegenerativas: un nuevo enfoque preventivo y terapeútico / Omega-3 fatty acids, neurodegenerative and psychiatric diseases: a new preventive and therapeutic approach

Psychiatric depression and neurodegenerative diseases, such as Alzheimer's disease and multiple sclerosis, have shown a considerable increase in recent decades, particularly in Western countries. These diseases are closely related to the age, socioeconomic status, employment conditions, physical activity, family history or genetic, and in recent years dietary patterns. Omega-3 long-chain polyunsaturated fatty acids (LCPUFA) from marine origin are decisive factors in the prevention and/or treatment of diseases such as cardiovascular diseases, and most recently in psychiatric and neurodegenerative disorders. There is evidence that supplementation with omega-3 LCPUFA may help in preventing the development or in ameliorating the progression of both psychiatric and neurodegenerative diseases. Different clinical trials have demonstrated the efficacy of omega-3 LCPUFA in the prevention and or treatment of neurodegenerative diseases. This review discusses different evidences about the role of omega-3 LCPUFA in the protection against neurodegenerative and psychiatric diseases.

Las enfermedades psiquiátricas y neurodegenerativas han experimentado un considerable incremento en las últimas décadas, particularmente en los países de occidente, destacando entre las de origen psiquiátrico la depresión y entre las neurodegenerativas la esclerosis múltiple y la enfermedad de Alzheimer. Estas enfermedades están estrechamente relacionadas con la edad, nivel socioeconómico, actividad laboral, actividad física, antecedentes familiares o genéticos, y en los últimos años con los patrones dietarios. Los ácidos grasos poliinsaturados de cadena larga (AGPICL) omega-3 de origen marino son considerados actualmente nutrientes determinantes para la prevención y/o el tratamiento de las enfermedades cardiovasculares y más recientemente se ha demostrado el beneficio de la suplementación con AGPICL omega-3 en la prevención y/o el retardo de la progresión de enfermedades psiquiátricas y neurodegenerativas. Diferentes ensayos clínicos han demostrado la eficacia de los AGPICL omega-3 en la prevención y/o tratamiento de enfermedades neurodegenerativas. En esta revisión se discuten diferentes evidencias sobre el rol de los AGPICL omega-3 en la protección de patologías psiquiátricas y neurodegenerativas, destacando el importante rol que tiene la adecuada nutrición en esta prevención.

CINCA Syndrome.

CINCA syndrome is a genetic disorder characterized by early onset of recurrent fever, rash, progressive articular and neurological involvement. We report a 7-year-old girl with CINCA syndrome with an infrequent manifestation of retinal vasculitis and a relative paucity of neurological signs. She had a de novo F309S mutation in exon 3 of CIAS1 gene on chromosome 1.This is the first report of this entity from India.

Herbal medicines in the treatment of psychiatric and neurological disorders

This review will indicate the quality of the evidence supporting the clinical effects of a number of commonly used types of herbal medicines for psychiatric and neurological disorders. We conducted a review of literature to understand the biochemical and evidential bases for the use of herbs in psychiatric and neurological disorders as follow: 1] Alzheimer's disease, 2] Depression, 3] Anxiety, 4] Insomnia, 5] Substance use disorders, 6] Attention deficit/hyperactivity disorder [ADHD], 7] Migraine. Evidences support use of Ginkgo biloba, Huperzine A, Galantamine, Melissa officinalisand Salvia officinalis for Alzheimer's disease; St. John's wort, Lavender. and Saffron for depression; Passionflower, and Kava, for anxiety disorders; Valerian and English Lavender for sleep disorders; Hypericum for substance related disorders; Ginkgo biloba, and Passionflower for ADHD; and feverfew, and Butterbur root for migraine. The highest level of confidence derives from well-designed, randomized, double blind controlled studies. Herbs may have beneficial effects in variety of psychiatric and neurological disorder; however we must consider their potential side effects and drug-drug interactions

Recent developments in the therapeutic potential of cannabinoids

OBJECTIVE: To examine the recent evidence that marijuana and other cannabinoids have therapeutic potential. METHODS: Literature published since 1997 was searched using the following terms: cannabinoid, marijuana, THC, analgesia, cachexia, glaucoma, movement, multiple sclerosis, neurological, pain, Parkinson, trial, vomiting. Qualifying clinical studies were randomized, double-blind, and placebo-controlled. Selected open-label studies and surveys are also discussed. RESULTS: A total of 15 independent, qualifying clinical trials were identified, of which only three had more than 100 patients each. Two large trials found that cannabinoids were significantly better than placebo in managing spasticity in multiple sclerosis. Patients self-reported greater sense of motor improvement in multiple sclerosis than could be confirmed objectively. In smaller qualifying trials, cannabinoids produced significant objective improvement of tics in Tourette's disease, and neuropathic pain. A new, non-psychotropic cannabinoid also has analgesic activity in neuropathic pain. No significant improvement was found in levodopa-induced dyskinesia in Parkinson's Disease or post-operative pain. No difference from active placebo was found for management of cachexia in a large trial. Some immune system parameters changed in HIV-1 and multiple sclerosis patients treated with cannabinoids, but the clinical significance is unknown. Quality of life assessments were made in only three of 15 qualifying clinical trials. CONCLUSION: Cannabinoids may be useful for conditions that currently lack effective treatment, such as spasticity, tics and neuropathic pain. New delivery systems for cannabinoids and cannabis-based medicinal extracts, as well as new cannabinoid derivatives expand the options for cannabinoid therapy. More well-controlled, large clinical tests are needed, especially with active placebo.

Neuroprotective role of melatonin in oxidative stress vulnerable brain.

The brain is deficient in oxidative defense mechanisms and hence is at greater risk of damage mediated by reactive oxygen species (ROS) resulting in molecular and cellular dysfunction. Emerging evidence suggesting the activation of glutamate gated cation channels, may be another source of oxidative stress, leading to neuronal degeneration. Oxidative stress has been implicated in the development of neurodegenerative diseases like Parkinsonism, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, epileptic seizures, and stroke. Melatonin, the pineal hormone, acts as a direct free radical scavenger and indirect antioxidant. It is suggested that the increase in neurodegenerative diseases is attributable to a decrease in the levels of melatonin with age. Melatonin has been shown to either stimulate gene expression for the antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase) or to increase their activity. Additionally, it neutralizes hydoxyl radical, superoxide radical, peroxyl radical, peroxynitrite anion, singlet oxygen, hydrogen peroxide, nitric oxide, and hypochlorous acid. Unlike other antioxidants, melatonin can easily cross all morphophysiological barriers, e.g., the blood brain barrier, and enters cells and subcellular compartments. Though evidence are accumulating to suggest the potential of melatonin in neurodegenerative conditions, much information needs to be generated before the drug can find place in neurology clinics.

Botulinum toxin: a dreaded toxin for use in human being.

Botulinum toxin is a dreaded biological toxin elaborated by Clostridium botulinum. The action of this toxin is to cause paralysis of both voluntary and involuntary muscles. The unique property of paralysing capability of muscles has been used for the benefit of human beings. Dr Allan Scot, an ophthalmologist, first used the toxin in a patient with squint in 1981 and since then the botulinum toxin is being used in various disorders characterised by muscle overactivity such as spasticity in both children and adult, dystonic conditions such as blepharospasm, cervical dystonia, spasmodic dysphonia, writer's cramp, etc, hemifacial spasm and headache. Its main action is at the terminal nerve endings of myoneural junction and it prevents release of acetylcholine from vesicles thus causing chemical denervation. Its action persists for 3 to 4 months on an average. Its side effects such as drooping, diplopia, dysphagia, depending on the sites of injection, are few and usually transient. Generalised anaphylaxis is almost unknown. Now botulinum toxin is being used in non-neurological conditions where muscles are under spasmodic state such as achalasia cardia, anal fissure, spasm of urethral sphincter, etc. Because of wider safety range and fewer complications, botulinum toxin has been an important therapeutic armamentarium in different branches of medicine and surgery.

Methyl-prednisolone in neurologic complications of Mycoplasma pneumonia.

In patients with Mycoplasma pneumonia extrapulmonary manifestations such as encephalitis, meningitis, cerebellar and brain stem involvement, cranial nerve lesions, peripheral neuropathy, polymyositis have been observed. We report a 16-year-old girl with M. pneumonia infection, acute behavioral changes and coma. Treatment with high dose methyl-prednisolone and clarithromycin led to rapid clinical improvement.

Neuropathic pain treatment with aminoglycosides

Different diagnostic and therapeutic modalities have to be employed in the management of various types of neuropathic pain. Taking into consideration the ototoxicity and neurotoxicity of aminoglycosides and local anaesthetic properties of bupivacaine, a combination of 1 gm streptomycin with 0.5% bupivacaine was used in 20 patients to relief the neropathic pains of post herpetic neuralgia, trigeminal neuralgia and nerve entrapment pain with favourable result. The overall pain relief in the three groups was 60% [good to excellent], 25% [fair], 15% [no significant relief]